Nov 30, 2018 7:00am EST Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update
Nov 20, 2018 7:00am EST Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
Oct 31, 2018 7:00am EDT Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19
Oct 25, 2018 7:00am EDT Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference
Oct 18, 2018 7:00am EDT Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018
Sep 12, 2018 7:00am EDT Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)
Sep 04, 2018 7:00am EDT Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year
Aug 31, 2018 7:00am EDT Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update
Aug 29, 2018 7:00am EDT Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aug 21, 2018 7:00am EDT Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis
